PDF herunterladen
Dtsch Med Wochenschr 2012; 137(49): 2577-2580
DOI: 10.1055/s-0032-1327268
Verdauungs- und Stoffwechselkrankheiten | Commentary
Gastroenterologie, Onkologie, Prävention
© Georg Thieme Verlag KG Stuttgart · New York

Kolorektales Karzinom – Was gibt’s Neues?

Colorectal carcinoma: what’s new?
C. Pox
1   Medizinische Universitätsklinik, Knappschaftskrankenhaus Bochum, Klinikum der Ruhr-Universität Bochum
,
W. Schmiegel
1   Medizinische Universitätsklinik, Knappschaftskrankenhaus Bochum, Klinikum der Ruhr-Universität Bochum
,
A. Reinacher-Schick
1   Medizinische Universitätsklinik, Knappschaftskrankenhaus Bochum, Klinikum der Ruhr-Universität Bochum
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. November 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Schlüsselwörter

kolorektales Karzinom - Prävention - Screening - adjuvante Therapie - Regorafenib

Keywords

colorectal carcinoma - prevention - screening - adjuvant treatment - Regorafenib
 

  • Literatur

  • 1 Ahlquist DA, Zou H, Domanico M et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142: 248-256
    CrossrefPubMedSuche in Google Scholar
  • 2 Allegra CJ, Lakomy R, Tabernero J et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. J Clin Oncol 2012; 30 (suppl; abstr 3505)
    PubMedSuche in Google Scholar
  • 3 André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116
    CrossrefPubMedSuche in Google Scholar
  • 4 Arnold D, André T, Bennouna J et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 2012; 30 (suppl; abstr CRA3503)
    PubMedSuche in Google Scholar
  • 5 Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systmatic review and meta-analysis. JAMA 2011; 305: 2335-2342
    CrossrefPubMedSuche in Google Scholar
  • 6 Haller DG, O‘Connell M, Cartwright TH et al. Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. J Clin Oncol 2012; 30 (suppl; abstr 3522)
    PubMedSuche in Google Scholar
  • 7 Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471
    CrossrefPubMedSuche in Google Scholar
  • 8 Mitry E, Guiu B, Cosconea S et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010; 59: 1 383-1388
    CrossrefPubMedSuche in Google Scholar
  • 9 Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
    CrossrefPubMedSuche in Google Scholar
  • 10 Pox CP, Altenhofen L, Brenner H et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012; 142: 1460-1467
    CrossrefPubMedSuche in Google Scholar
  • 11 Quintero E, Castells A, Bujanda L et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706
    CrossrefPubMedSuche in Google Scholar
  • 12 Ruers TJ, Wiering B, van der Sirjp JR et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50: 1036-1041
    CrossrefPubMedSuche in Google Scholar
  • 13 Sanoff HK, Carpenter WR, Martin CF et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104: 211-27
    CrossrefPubMedSuche in Google Scholar
  • 14 Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-2357
    CrossrefPubMedSuche in Google Scholar
  • 15 Sinicrope FA, Foster NR, Thibodeau SN et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875
    CrossrefPubMedSuche in Google Scholar
  • 16 Van Cutsem E, Sobrero AF, Siena S et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 2012; 30 (suppl; abstr 3502)
    PubMedSuche in Google Scholar
  • 17 Zauber AG, Winawer SJ, O’Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 3 66: 687-696
    PubMedSuche in Google Scholar